Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has …

The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of
solid tumors with high tumor mutational burden (TMB-high;≥ 10 variants/Mb). However, the …

Tumor Mutational Burden and Response Rate to PD-1 Inhibition | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Purpose To determine the activity of pembrolizumab as neoadjuvant immunotherapy before
radical cystectomy (RC) for muscle-invasive bladder carcinoma (MIBC) for which standard …

Background No systemic therapies have been approved for the treatment of advanced
cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy …

Immunotherapy induces durable responses in a subset of patients with cancer. High tumor
mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors …

Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint
inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of …

Background Cancers with a defective DNA mismatch repair (dMMR) system contain
thousands of mutations most frequently located in monomorphic microsatellites and are …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome …